Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response.
Liao JB, Dai JY, Reichow JL, Lim JB, Hitchcock-Bernhardt KM, Stanton SE, Salazar LG, Gooley TA, Disis ML. Liao JB, et al. Among authors: stanton se. J Immunother Cancer. 2024 Nov 9;12(11):e010251. doi: 10.1136/jitc-2024-010251. J Immunother Cancer. 2024. PMID: 39521614 Free PMC article.
Associations of Multiparametric Breast MRI Features, Tumor-Infiltrating Lymphocytes, and Immune Gene Signature Scores Following a Single Dose of Trastuzumab in HER2-Positive Early-Stage Breast Cancer.
Kennedy LC, Kazerouni AS, Chau B, Biswas D, Alvarez R, Durenberger G, Dintzis SM, Stanton SE, Partridge SC, Gadi V. Kennedy LC, et al. Among authors: stanton se. Cancers (Basel). 2023 Aug 30;15(17):4337. doi: 10.3390/cancers15174337. Cancers (Basel). 2023. PMID: 37686613 Free PMC article.
Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.
Mohammed A, Dashwood RH, Dickinson S, Disis ML, Jaffee EM, Johnson BD, Khleif SN, Pollak MN, Schlom J, Shoemaker RH, Stanton SE, Wondrak GT, You M, Zhu H, Miller MS. Mohammed A, et al. Among authors: stanton se. J Cancer Prev. 2021 Dec 30;26(4):309-317. doi: 10.15430/JCP.2021.26.4.309. J Cancer Prev. 2021. PMID: 35047458 Free PMC article.
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Liao JB, Gwin WR, Urban RR, Hitchcock-Bernhardt KM, Coveler AL, Higgins DM, Childs JS, Shakalia HN, Swensen RE, Stanton SE, Tinker AV, Wahl TA, Ancheta RG, McGonigle KF, Dai JY, Disis ML, Goff BA. Liao JB, et al. Among authors: stanton se. J Immunother Cancer. 2021 Sep;9(9):e003122. doi: 10.1136/jitc-2021-003122. J Immunother Cancer. 2021. PMID: 34531249 Free PMC article.
27 results